Defining Remission With Etanercept in AS in Real Life Clinical Practice

• Status: Completed
• Trial end date: 2017-04-26
• Target enrollment: 0
• Participant gender: All

Summary

Determine which remission criterion at Month 6 predicts remission at Month 12 the best.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Etanercept

Criteria

Inclusion Criteria:

1. Patients with AS who start treatment with Etanercept according to prevailing reimbursement criteria and dosing in line with SmPC.

1. First cohort: Etanercept is the first biological product prescribed

2. Second cohort: Etanercept is the second biological product prescribed

2. Capable of understanding and willing to provide signed and dated written, voluntary informed consent before any protocol-specific procedures are performed.

3. 18 years of age or older at time of consent

4. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria:

1. History of or current psychiatric illness that would interfere with the subject's ability to comply with protocol requirements or to give informed consent.